Skip to main content
BrainCited

Omega-3 Fatty Acids (DHA/EPA) Depression-Related Cognitive Dysfunction

B エビデンス 少なくとも1件のランダム化試験がこれを支持しており、おおむね一貫した結果が得られています。

Research suggests fish oil supplements may help support memory function and are also associated with improved outcomes in people experiencing depression-related cognitive symptoms.

<\/script>\n
`; }, get iframeSnippet() { const domain = 'braincited.com'; const params = 'ingredient\u003Domega\u002D3\u002Ddha\u002Depa\u0026condition\u003Ddepression\u002Dcognitive'; return ``; }, get activeSnippet() { return this.method === 'script' ? this.scriptSnippet : this.iframeSnippet; }, copySnippet() { navigator.clipboard.writeText(this.activeSnippet).then(() => { this.copied = true; setTimeout(() => { this.copied = false; }, 2000); }); } }" @keydown.escape.window="open = false" @click.outside="open = false">

Embed This Widget

Style



      
      
    

Widget powered by . Free, no account required.

B

結論

Research suggests fish oil supplements may help support memory function and are also associated with improved outcomes in people experiencing depression-related cognitive symptoms.

Key Study Findings

Review
The Clinical Implications of Ashwagandha (Withania somnifera L.) with a Special Reference to Side Effects-A …
Dose: None vs: None Outcome: None 効果: None None

対象集団: narrative review of ashwagandha clinical trials and basic research (1994-present)

preclinical animal/in vitro study
Ashwagandha (Withania somnifera (L.) dunal) root extract containing withanolide a alleviates depression-like behavior in mice …
Dose: 60 and 100 mg/kg (mice); 100 and 200 µg/mL (HT-22 cells); withanolide A 1.56 and 3.12 µg/mL vs: Placebo 効果: None None
Review
[Pharmacotherapies for insomnia].
Dose: Z-drugs, melatonin, orexin antagonists vs: None Outcome: Insomnia treatment efficacy and safety 効果: None None

対象集団: Adults with chronic insomnia

In Vitro
Oxytocin and Vasopressin Gene Expression in the Brain as Potential Biomarkers for Cannabidiol Therapeutic Efficacy.
Dose: Cannabidiol (CBD) vs: Vehicle control Outcome: Oxytocin and vasopressin gene expression 効果: None None

対象集団: EAE mouse model (multiple sclerosis)

Meta-Analysis
Effects of vitamins and polyunsaturated fatty acids on cognitive function in older adults with mild …
Dose: None vs: Control Outcome: Cognitive function 効果: SMD = 0.58, 95% CI = [0.20, 0.96] P = 0.003

対象集団: Patients with mild cognitive impairment

Controlled Clinical Trial
Prolonging effects of Valeriana fauriei root extract on pentobarbital-induced sleep in caffeine-induced insomnia model mice …
Dose: 5 g/kg or 10 g/kg (as VF) vs: Caffeine-induced insomnia without VF Outcome: Sleep latency and duration (pentobarbital-induced) 効果: None None

対象集団: Caffeine-induced insomnia model mice

Key Statistics

15

研究数

2500

参加者数

Positive

B

グレード

Referenced Papers

La Revue du … 2024
Nature reviews. Disease … 2021 163 件の引用
The Senior care … 2021 2 件の引用
Journal of ethnopharmacology 2020 85 件の引用
Current neurology and … 2019 11 件の引用
Sleep medicine 2017 95 件の引用
Current treatment options … 2017 56 件の引用
Clinical therapeutics 2016 328 件の引用
Molecular nutrition & … 2015 18 件の引用
The Cochrane database … 2003 263 件の引用

Dosage & Usage

mg = milligrams · mcg = micrograms (1,000× smaller) · IU = International Units

一般的な使用量

general:
1,000-2,000 mg combined DHA/EPA per day
cognitivesupport:
1,000-1,700 mg/day (optimal dose-response curve)

上限量: 3,000 mg/day combined DHA/EPA (FDA GRAS)

研究で検討された用量

用量 期間 効果 N
None -- Positive --
60 and 100 mg/kg (mice); 100 and 200 µg/mL (HT-22 cells); withanolide A 1.56 and 3.12 µg/mL -- Positive --
Z-drugs, melatonin, orexin antagonists -- Positive --
Cannabidiol (CBD) -- Positive --
None -- Positive --
5 g/kg or 10 g/kg (as VF) -- Positive --
10, 25, or 50 mg/kg body weight ashwagandha extract (AE, 35% withanolide glycosides, Shoden) -- Positive --
None -- Mixed --

推奨摂取タイミング: With meals containing fat for better absorption

Safety & Side Effects

報告されている副作用

  • Fishy aftertaste or burping
  • Mild gastrointestinal discomfort
  • Potential increased bleeding time at very high doses
  • May lower blood pressure slightly

既知の相互作用

  • Anticoagulants and antiplatelet drugs (may increase bleeding risk at high doses)
  • Blood pressure medications (additive hypotensive effect)
  • Orlistat (may reduce omega-3 absorption)

耐容上限摂取量: 3,000 mg/day combined DHA/EPA (FDA GRAS)

サプリメントの摂取を開始する前に、必ず医療専門家にご相談ください。

Frequently Asked Questions

Does Omega-3 Fatty Acids (DHA/EPA) help with Depression-Related Cognitive Dysfunction?
Based on 15 studies with 2,500 participants, there is moderate evidence from clinical studies that Omega-3 Fatty Acids (DHA/EPA) may support Depression-Related Cognitive Dysfunction management. Our evidence grade is B (Good Evidence).
How much Omega-3 Fatty Acids (DHA/EPA) should I take for Depression-Related Cognitive Dysfunction?
Studies have used various dosages. A commonly studied range is 1,000-2,000 mg combined DHA/EPA per day. Always consult your healthcare provider before starting any supplement regimen.
Are there side effects of Omega-3 Fatty Acids (DHA/EPA)?
Reported side effects may include Fishy aftertaste or burping, Mild gastrointestinal discomfort, Potential increased bleeding time at very high doses, May lower blood pressure slightly. Most side effects are mild and dose-dependent. Consult your doctor if you experience any adverse reactions.
How strong is the evidence for Omega-3 Fatty Acids (DHA/EPA) and Depression-Related Cognitive Dysfunction?
We rate the evidence as Grade B (Good Evidence). This rating is based on 15 peer-reviewed studies with 2,500 total participants. The overall direction of effect is positive.

に関する他の成分: Depression-Related Cognitive Dysfunction

References

  1. [1] Kaj Winther. Nutrients. 2026. The Clinical Implications of Ashwagandha (Withania somnifera L.) with a Special Reference to Side Effects-A Review. doi:10.3390/nu18050871 PubMed
  2. [2] Hyeongyeong Kim et al.. J Ethnopharmacol. 2025. Ashwagandha (Withania somnifera (L.) dunal) root extract containing withanolide a alleviates depression-like behavior in mice by enhancing the brain-derived neurotrophic … doi:10.1016/j.jep.2024.119224 PubMed
  3. [3] Jing Chang et al.. Eur J Nutr. 2024. Effects of vitamins and polyunsaturated fatty acids on cognitive function in older adults with mild cognitive impairment: a meta-analysis of … doi:10.1007/s00394-024-03324-y PubMed
  4. [4] Christa M Frodella et al.. Biomedicines. 2024. Oxytocin and Vasopressin Gene Expression in the Brain as Potential Biomarkers for Cannabidiol Therapeutic Efficacy. doi:10.3390/biomedicines12061273 PubMed
  5. [5] Marie-Françoise Vecchierini et al.. Rev Prat. 2024. [Pharmacotherapies for insomnia]. PubMed
  6. [6] Sindgi Vasudeva Murthy et al.. Prev Nutr Food Sci. 2022. Hydroalcoholic Extract of Ashwagandha Improves Sleep by Modulating GABA/Histamine Receptors and EEG Slow-Wave Pattern in In Vitro - In Vivo … doi:10.3746/pnf.2022.27.1.108 PubMed
  7. [7] Vincent Beliveau et al.. Neuroimage Clin. 2022. Revisiting brain iron deficiency in restless legs syndrome using magnetic resonance imaging. doi:10.1016/j.nicl.2022.103024 PubMed
  8. [8] Misato Ota et al.. J Ethnopharmacol. 2022. Prolonging effects of Valeriana fauriei root extract on pentobarbital-induced sleep in caffeine-induced insomnia model mice and the pharmacokinetics of its … doi:10.1016/j.jep.2022.115625 PubMed
  9. [9] Yulin Sun et al.. BMJ Open. 2022. Melatonin supplementation for the treatment of infantile spasms: protocol for a randomised placebo-controlled triple-blind trial. doi:10.1136/bmjopen-2021-057970 PubMed
  10. [10] Mauro Manconi et al.. Nat Rev Dis Primers. 2021. Restless legs syndrome. doi:10.1038/s41572-021-00311-z PubMed
  11. [11] Heba M A Khalil et al.. J Ethnopharmacol. 2021. Ashwagandha (Withania somnifera) root extract attenuates hepatic and cognitive deficits in thioacetamide-induced rat model of hepatic encephalopathy via induction of … doi:10.1016/j.jep.2021.114141 PubMed
  12. [12] Rodiya Manor et al.. J Ethnopharmacol. 2021. Characterization of pharmaco-EEG fingerprint and sleep-wake profiles of Lavandula angustifolia Mill. essential oil inhalation and diazepam administration in rats. doi:10.1016/j.jep.2021.114193 PubMed
  13. [13] Brittany R Block et al.. Sr Care Pharm. 2021. Online Promotion of "Brain Health" Supplements. doi:10.4140/TCP.n.2021.489 PubMed
  14. [14] Isabella C Arellanes et al.. EBioMedicine. 2020. Brain delivery of supplemental docosahexaenoic acid (DHA): A randomized placebo-controlled clinical trial. doi:10.1016/j.ebiom.2020.102883 PubMed
  15. [15] Nawab John Dar et al.. J Ethnopharmacol. 2020. Neurodegenerative diseases and Withania somnifera (L.): An update. doi:10.1016/j.jep.2020.112769 PubMed
  16. [16] Jennifer L Martin et al.. J Clin Sleep Med. 2020. The Veterans Administration and Department of Defense clinical practice guidelines for the diagnosis and management of sleep disorders: what does … doi:10.5664/jcsm.8486 PubMed
  17. [17] Jerome Sarris et al.. J Psychiatr Res. 2019. L-theanine in the adjunctive treatment of generalized anxiety disorder: A double-blind, randomised, placebo-controlled trial. doi:10.1016/j.jpsychires.2018.12.014 PubMed
  18. [18] Valérie Cochen De Cock et al.. Curr Neurol Neurosci Rep. 2019. Sleep Disorders in Wilson's Disease. doi:10.1007/s11910-019-1001-4 PubMed
  19. [19] Giovanni Rizzo et al.. Sleep Med. 2017. Brain imaging and networks in restless legs syndrome. doi:10.1016/j.sleep.2016.07.018 PubMed
  20. [20] G Iolascon et al.. J Nutr Health Aging. 2017. Are Dietary Supplements and Nutraceuticals Effective for Musculoskeletal Health and Cognitive Function? A Scoping Review. doi:10.1007/s12603-016-0823-x PubMed
  21. [21] Amy W Amara et al.. Curr Treat Options Neurol. 2017. Treatment of Sleep Dysfunction in Parkinson's Disease. doi:10.1007/s11940-017-0461-6 PubMed
  22. [22] Jennifer L Schroeck et al.. Clin Ther. 2016. Review of Safety and Efficacy of Sleep Medicines in Older Adults. doi:10.1016/j.clinthera.2016.09.010 PubMed
  23. [23] Yoan Cherasse et al.. Mol Nutr Food Res. 2015. Zinc-containing yeast extract promotes nonrapid eye movement sleep in mice. doi:10.1002/mnfr.201500082 PubMed
  24. [24] Anna K Morin et al.. Pharmacotherapy. 2007. Therapeutic options for sleep-maintenance and sleep-onset insomnia. doi:10.1592/phco.27.1.89 PubMed
  25. [25] Chun-Su Yuan et al.. Anesth Analg. 2004. The gamma-aminobutyric acidergic effects of valerian and valerenic acid on rat brainstem neuronal activity. doi:10.1213/01.ANE.0000096189.70405.A5 PubMed
  26. [26] M Malouf et al.. Cochrane Database Syst Rev. 2003. Folic acid with or without vitamin B12 for cognition and dementia. doi:10.1002/14651858.CD004514 PubMed
  27. [27] B Enkvetchakul et al.. Poult Sci. 1995. Influence of diethyl maleate and cysteine on tissue glutathione and growth in broiler chickens. doi:10.3382/ps.0740864 PubMed

FDAに関する免責事項: これらの記述は米国食品医薬品局(FDA)による評価を受けていません。本ウェブサイトの製品および情報は、疾病の診断、治療、治癒、または予防を目的としたものではありません。表示されているエビデンスグレードは、公開された査読済み研究の分析に基づいており、医療上の助言を構成するものではありません。サプリメントの摂取を開始する前に、必ず医療専門家にご相談ください。